Stockscreener 앱 받기
0.77
2.53%
-0.02
시간 외 거래:
.77
Longeveron Inc 주식(LGVN)의 최신 뉴스
Longeveron receives SME status from European regulator By Investing.com - Investing.com Nigeria
Longeveron receives SME status from European regulator - Investing.com UK
Longeveron Granted SME Status by European Medicines Agency - Moomoo
Longeveron Inc. Awarded SME Status by European Medicines Agency, Enhancing Drug Development Opportunities - Quiver Quantitative
Biotech Longeveron wins EMA SME status, where SME drugs saw 89% OKs - Stock Titan
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Number of shareholders of Longeveron Inc. – BOATS:LGVN - TradingView
LGVN Q1 2026 Earnings: Deeper Losses Weigh on Shares as Clinical Progress ContinuesGross Profit Margin - newsline.com
Longeveron Announces CFO Transition to Internal Successor - TipRanks
LongeveronOn June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026SEC Filing - TradingView
Longeveron (NASDAQ: LGVN) CFO Lisa Locklear to step down, controller eyed as successor - Stock Titan
Longeveron to Present at BIO International Convention 2026 - BioSpace
Stem cell firm Longeveron seeks Alzheimer’s, heart partners at BIO 2026 - Stock Titan
LGVN Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D AdvancesShare Repurchase Impact - newsline.com
LGVN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Clinical-Stage Biotech Navigates Costs - newsline.com
Longeveron Inc. (LGVN) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEarnings Trend Analysis - The Legal Advocate
Longeveron Inc. (LGVN) Extends Decline: Tests Key Support at $0.74 After 4.9% DropDebt Free Companies - newsline.com
Longeveron (LGVN) Stock Forecast & Analyst Ratings - Moomoo
Longeveron Inc. Q1 2026 Earnings: EPS Misses Estimates Despite Stock RallyAdjusted Earnings Analysis - newsline.com
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design - MSN
LGVN Should I Buy - Intellectia AI
Longeveron CEO outlines strategy ahead of August trial data - Investing.com India
Longeveron CEO outlines strategy ahead of August trial data By Investing.com - Investing.com Nigeria
Longeveron Inc. (LGVN) Edges Higher Amid Stabilization at $0.72Dividend Growth Stocks - The Legal Advocate
[ARS] Longeveron Inc. SEC Filing - Stock Titan
Longeveron (NASDAQ: LGVN) plans reverse split, bigger share pool and incentive plan - Stock Titan
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering ... - Caledonian Record
Longeveron Issues Letter to Stockholders Highlighting - GlobeNewswire
Longeveron anticipates August 2026 ELPIS II readout while shifting to an asset-light partnering model - MSN
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift By Investing.com - Investing.com Nigeria
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift - Investing.com
[SCHEDULE 13G] Longeveron Inc. Passive Investment Disclosure (>5%) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Longeveron Earnings Call: Trial Milestones Amid FDA Hurdles - TipRanks
Longeveron Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
1.27%
1.43%
자본화:
|
볼륨(24시간):